Maria Fardis ends a two-year CEO hia­tus; More lead­er­ship turnover on the menu at Gala­pa­gos

→ Fol­low­ing her res­ig­na­tion from Io­vance, Maria Fardis piv­ot­ed to Fra­zier Life Sci­ences as a ven­ture part­ner. But she’s back in the sad­dle at a Fra­zier up­start, tak­ing over for Mark Bar­rett as CEO of San Diego-based IL-11 biotech Lassen Ther­a­peu­tics. Fardis al­so chairs the board at Ob­sid­i­an Ther­a­peu­tics and has a board seat at CRISPR Ther­a­peu­tics.

CMC-re­lat­ed de­lays ham­pered po­ten­cy as­says for Io­vance’s tu­mor in­fil­trat­ing lym­pho­cyte ther­a­py li­fileu­cel, and Fardis stepped down not even 24 hours af­ter the BLA for li­fileu­cel stalled out again in 2021. To this day, a per­ma­nent re­place­ment for in­ter­im chief and gen­er­al coun­sel Fred­er­ick Vogt hasn’t been named.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER